NIMOTOP TABLET 30 mg

TABLET, FILM COATED

**POSOLOGY AND METHOD OF ADMINISTRATION** **Posology** Unless otherwise prescribed, the following dosage is recommended: The recommended procedure is administration of Nimotop infusion solution for 5–14 days, followed by a daily dose of 6 x 2 Nimotop tablets (6 x 60 mg nimodipine) In patients who develop adverse reactions the dose should be reduced as necessary or the treatment discontinued. **Patients with hepatic impairment** Severely disturbed liver function, particularly liver cirrhosis, may result in an increased bioavailability of Nimodipine due to a decreased first-pass capacity and a reduced metabolic clearance. The effects and side-effects, e.g. reduction in blood-pressure, may be more pronounced. In such cases the dose should be reduced, depending on the blood pressure; or, if necessary, discontinuation of the treatment should be considered. **Administration** Administration of Nimotop tablets is recommended for about 7 days after the end of 5–14 days infusion therapy with Nimotop infusion solution. In general, the tablets should be swallowed in whole with a little liquid, independently of meal times. Grapefruit juice is to be avoided (see “Interactions with other medicinal products and other forms of interaction” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). The interval between successive doses must not be less than 4 h. **Duration of use:** \- Prophylactic Use: After the end of the infusion therapy, it is advisable to continue with oral administration of 6 x 60 mg Nimotop tablets daily at four-hourly intervals for about further 7 days. \- Therapeutic Use: After intravenous application, oral administration of 6 x 60 mg Nimotop tablet per day at four-hourly intervals for 7 days is recommended.